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Resumo 
 
Este relatório descreve as actividades como coordenadora de estudos 
estagiária, na Unidade de Investigação Clínica (UIC) do Instituto Português de 
Oncologia do Porto (IPOP). Este estágio foi parte integrante das actividades 
curriculares do segundo ano do Mestrado em Biomedicina Farmacêutica da 
Universidade de Aveiro. 
O  estágio decorreu entre 21 de Janeiro de 2013 e 4 de Outubro de 2013, com 
o  principal objectivo em adquirir experiência e especialização na coordenação 
de ensaios clínicos em oncologia.  
No documento é apresentado o estado de arte de arte da investigação clínica 
com ênfase na actual situação em Portugal bem como em oncologia. 
Na fase inicial do estágio realizei treino genérico em Boas Práticas Clínicas e 
sistemas de Captura de Dados Electrónicos e familiarizei-me com terminologia 
e sistemas classificação/avaliação próprios da área de oncologia para suportar 
as actividades de coordenação de ensaios clínicos no contexto dos protocolos 
de oncologia.  
Na UIC, participei em vários estudos de fase II e III de 9 clínicas de patologia: 
Urologia, Ginecologia, Digestivos, Pulmão, Pele e Tecidos Moles, Cabeça e 
Pescoço, Onco-Hematologia, Mama e Pediatria. Dentro destas clínicas, 
participei intensivamente e adquiri mais autonomia nos ensaios clínicos da 
patologia de Digestivos. A clínica de Onco-Hematologia, agrega os protocolos 
de ensaios clínicos com procedimentos mais complexos. 
Como coordenadora de ensaios clínicos pude participar intensivamente nas 
actividades de condução de um ensaio clínico, nomeadamente: Período de 
Randomização incluindo Rastreio e Randomização de doentes, Visitas 
Clínicas e Visitas de Monitorização. 
A experiência adquirida ao longo do estágio curricular foi muito enriquecedora 
e permitiu-me adquirir capacidades e competências profissionais e 
interpessoais e aprender a enfrentar situações inesperadas, desenvolvendo 
estratégias para lidar com as mesmas. Para além disso possibilitou-me a 
consolidar e aplicar os conhecimentos teóricos adquiridos no Curso de 
Mestrado nas diferentes fases de coordenação dos estudos. 
Em conclusão, ao longo do estágio adquiri competências, motivação e 
experiência para enveredar por uma carreira na área de investigação clínica, 
especialmente como Coordenadora de Ensaios Clínicos. 
 
 
 
 I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Coordination of Clinical Trials, Clinical Trials, Pharmaceutical Medicine, Clinical 
Research, Phase II Clinical Trials, Phase III Clinical Trials, Oncology, IPO 
 
abstract 
 
This report describes my activities as study coordinator (SC) intern, at the 
“Unidade de Investigação Clínica” (UIC) in the Oncology Portuguese Institute of 
Porto (IPOP). This training occurred during the second year of the 
Pharmaceutical Biomedicine Master at the University of Aveiro. 
My internship took place between 21
st
 January, 2013 and 4
th
 October, 2013 
with the main objective to gain experience and expertise in oncology 
coordinating clinical trials. 
I present the state-of-the-art of clinical research with emphasis on current 
situation in Portugal as well as in oncology. 
At the beginning of internship I performed generic training in Good Clinical 
Practices (GCP) and Electronic Data Capture systems and familiarised myself 
with terminology and classification/assessment systems regarding the oncology 
area to support the clinical trial coordination activities in the context of the 
oncology protocols. 
In UIC, I participated in 6 phase II and 25 phase III clinical trials of 9 clinics of 
pathology: Urology, Gynaecology, Digestive, Lung, Soft Tissue and Skin, Head 
and Neck, Onco-Haematology, Breast and Paediatry. Within of these clinics, I 
intensively participated and acquired more autonomy in clinical trials of the 
Digestive pathology. The Onco-Haematology clinic includes the more complex 
procedures of the clinical trials protocols. 
As SC, I could intensively participate in the conduction clinical trial activities, 
namely:  Randomisation Period, including Screening and Randomisation of 
patients, Clinic Visits and Monitoring Visits. 
The experience gained during my curricular internship was very enriching and 
enabled me to acquire professional and interpersonal skills and competences 
and to face unexpected situations, developing strategies to deal with them. 
Additionally, it was possible to consolidate and apply the theoretical knowledge 
acquired during Master Course in Pharmaceutical Medicine at different stages 
of clinical trials coordination. 
In conclusion, during my curricular internship, I gathered the competences, 
motivation and experience to pursue a career in clinical research, particularly, 
as SC. 
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1. Introduction 
My internship within the scope of the Pharmaceutical Biomedicine Master´s degree, at the 
University of Aveiro, took place at the “Unidade de Investigação Clínica” (UIC) of “Instituto 
Português de Oncologia do Porto” (IPOP), from January 2013 to October 2013.  
The training report contemplates the clinical trial coordination activities developed in the UIC 
of IPOP. It is organised into five chapters. The chapter 1 - Introduction, contextualises my 
training and comprises a characterisation of the host institution primary and secondary 
training objectives my view of the state-of-the-art on the clinical research, addressing the 
current situation of clinical research in Portugal and in the oncology field. The content of this 
topic will be initiated with a brief approach to the clinical research in humans. Then, it will be 
addressed the global pharmaceutical Research and Development (R&D), where it will be 
focused the current difficulties, challenges and the strategies inherent to the pharmaceutical 
R&D process. Furthermore, it will be addressed the clinical trials classification based on 
study objectives and the current situation of clinical trials in Portugal, which will include the 
clinical trials regulatory framework, the sector characterisation, barriers and challenges and 
finally the strategies to improve the clinical trials activity. The last subtopic contemplates the 
recent data about the clinical oncology research on an European and National scope. The 
chapter 2 - Generic Training, presents the online training courses and my acquaintance with 
support tools in the context of clinical trials protocols. The chapter 3 - Specific Training, 
describes the clinical trial coordination activities according to the stage of clinical trial 
(initiation, conduction and closeout) that I experienced during my internship. The chapter 4 - 
Discussion, presents a critical view about my training experience. Finally, the chapter 5 - 
Conclusion, draws attention to the final considerations also resulting from my experience. 
1.1 Overview of the Host Institution 
1.1.1 Instituto Português de Oncologia do Porto 
IPOP is a highly differentiated institution that belongs to the National Health Service. The 
mission of this institution is to provide health care services, timely, patient-centered, not 
neglecting the prevention, research, training and education in the oncology scope with the 
goal of ensuring high levels of quality, humanism and efficiency (6). IPOP was transformed in 
an “Entidade Pública Empresarial” by the Decree-Law nº 233/2005, of December 29th (7). 
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Over the last years, the IPOP has performed an extensive investment in research (8). The 
Research Centre is a research unit recognised by Foundation for Science and Technology 
since 2004 (9). The general and long-term objective of Research Centre is the understanding 
of the pathobiologic mechanisms behind carcinogenesis, which ultimately will help improve 
the cancer prevention and/or treatment (10). Currently, this centre has the following structure 
(9, 10): the Cancer Genetics Group; the Cancer Epigenetic Group; the Molecular Oncology 
Group; the Experimental Pathology and Therapeutics Group; the Medical Physics and 
Radiation Protection Group and the UIC where I developed the majority of activities during 
my internship. The UIC will be presented, hereinafter, in more detail. 
The Tumour Bank, inaugurated in 2012 and located in the Service of Pathological Anatomy, 
will be a major support service for the cancer research (11). This functional unit enables, 
after a previous written authorisation by the patient, the harvest of tumour tissue samples 
which then are stored and used for biomedical research (11).  
The Portuguese Oncology School of Porto  provides education and professional integration 
of its students and professionals in the area of oncology, medicine, health and other 
complementary areas (12).  
Following it will be presented in detail the UIC, the unit of the IPOP devoted to the clinical 
trials. 
1.1.2 Unidade de Investigação Clínica 
During my internship in IPOP, I developed the majority of activities as Study Coordinator 
(SC) in UIC.  
The UIC was created on the year 2006 (13). The first main goal was to support the existing 
clinical trials and to promote the implementation and the execution of new clinical trials and 
also to ensure the compliance with respective protocols and procedures (4, 13). 
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Figure 1: The Organigram of the IPOP [adapted from(2)]. 
The” Unidade de Investigação Clínica” is depicted in the oval figure. 
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Therefore, to continue to pursuit the main goal established at the beginning, it was necessary 
to create the unit´s team not only to maintain the support and execution of clinical trials but 
also to attract new and best global clinical trials (4, 13). It started with one single responsible 
SC, and due to the results it increased to a team of 4 full time SCs [(Manuela Seixas 
personal communication) (MS p.c.)]. These members were divided by pathologies. Each SC 
was responsible for a specific group of pathology clinical trials (MS p.c.). On this way of work, 
each investigator’s team had its own SC and could develop a close work relation and also 
achieve the clinics objectives (MS p.c.). This strategy proved to be effective for achieving 
each clinical trial main objectives, gaining competitiveness between different teams and 
motivating a progressive growth of the number of recruited patients as well as of the clinical 
trials (see figures 2 and 3) (4, 13). 
 
 
Figure 2: Clinical trials recruitment rate in UIC of IPOP between 2007 and 2011 [adapted 
from (4)]. 
 
Figure 3: Authorised clinical trials in UIC of IPOP between 2007 and 2012 [adapted from 
(4)]. 
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This work lead not only to the growth of number of SCs, as it led to the increase of the 
number of infrastructures and facilities (3). In the beginning, there was a single room for the 4 
SCs and today there is a main infrastructure where each SC has its own office (3). Currently, 
the UIC has the following infrastructures (3):    
 9 rooms (offices), 3 monitoring rooms, 1 meeting room, 2 file (archive) areas (see 
figure 4) and 1 area of pharmaceutical services (clinical trials pharmacy); 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pharmaceutical facilities (clinical trials pharmacy) are not represented in figure 2 
because they are located in another building of IPOP. They are represented in the figure 1 at 
the green square. 
The human resources of UIC is represented in the figure 5 and involves 1 Medical 
Coordinator of UIC, 1 Manager of Good Clinical Practices (GCP) and Quality, 1 Operational 
Manager, 1 Financial Manager, 5 Study Coordinators, 4 Clinical Trial Assistants, 1 Financial 
Figure 4: Current plan of UIC [adapted from (3)].  
Legend 
1: Office (Manager of GCP and 
Quality) 
2: Office (Operational Manager) 
3: Office (Financial Manager) 
4: Office (SC) 
5: Office (SC) 
6: Office (SC) 
7: Office (SC) 
 
 
 
 
10: Office (Reception) 
11: Office (Financial Manager 
Assistant 
13: Meeting Room 
15: Monitoring Room 3 
16: File (archive) area 
17: Monitoring Room 2 
18: Monitoring Room 1 
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Manager Assistant, 1 Administrative and 2 Operational Assistants (1). Briefly, each UIC team 
member is responsible for (1):  
o Medical Coordinator represents the IPOP and technically assists IPOP Administration 
Board (AB), concerning clinical trials; proposes a Plan of UIC Activities and respective 
report to the AB; ensures the synchronisation with the several departments and services 
of IPOP involved in clinical trials and evaluate the educational needs of the team 
members and their performance; 
o Manager of GCP and quality proposes, develops and maintains the GCP System; 
proposes to the AB the Annual Plan and performs the Internal Audits; participates in the 
support team to the external audits and inspections and reviews the support 
documentation to the submission to the IPOP AB; 
o Operational Manager  manages UIC's daily activities and coordinates the activities of each 
UIC member; prepares, submits and accompanies the “Dossier of Approval Request to 
the conduction of a clinical trial at IPOP”; reviews, periodically, the records of clinical trials 
procedures  and informs the UIC Financial Manager, to allow the billing to the sponsor 
and prepares and participates in the support team to the internal and external audits and 
inspections; 
o Financial Manager evaluates, reviews and emits a financial opinion regarding the clinical 
trials financial protocols; interacts with the Financial Services, Pharmaceutical Services, 
UIC and sponsors to the bills emission regarding the services and procedures of the 
clinical trials protocols and complies with the procedure respective to the compensation of 
clinical trial participants’ travel expenses, in accordance with financial protocol; 
o SCs implement clinical trials, supporting the clinical trial team in every activities related 
with the preparation and organization of the procedures and documentation; ensure that 
the clinical trial team complies with the GCP and with the clinical trial protocol; participate 
in the Investigator’s meetings; maintain the clinical trial documentation up-to-date and 
archived, complying with the sponsor procedures; maintain the clinical trial procedures 
registry updated; schedule and give support to the monitoring visits; comply  with the 
procedure respective to the compensation of clinical trials participants’ travel expenses, in 
accordance with financial protocol and update the information about each clinical trial 
status, reporting it internally and to the sponsor; 
o Clinical Trial Assistants assist the SC on her activities, namely the archive of documents 
and its update, and scheduling the participants visits and exams; 
o Financial Manager Assistant assists the financial manager on her activities; 
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o Administrative supports the UIC team on every activity related with clinical trials, namely 
the preparation and internal distribution of clinical trials documentation and material; 
receives and distributes every correspondence and clinical trial material in the UIC, and 
dispatches to the exterior and controls and ensures the availability of the material 
necessary to the UIC functioning; 
o Operational Assistants transport the participant health records from other services to the 
UIC and vice-versa, as needed; track the patient health records location and update its 
registry and prepare the monitoring offices for each visit with the adequate material. 
Thus, IPOP  is a reference research centre to the clinical trials conducted in Portugal in the 
majority of pathologies treated in the institution (13). In coming years, UIC expects to 
maintain a sustained growth of performance and promote the participation in clinical trials of 
earlier phases, with the creation of a specific unit to phase I clinical trials (13).  
The operationalization of the work of UIC was achieved in accordance to its own regulation 
and procedures that all team members are aware of (1). The UIC performed its own 
Standard Operating Procedures (SOPs) to equalise the work of all SCs (14). In terms of 
revenue sharing, it was created a model that promotes the reinvestment in clinical research 
through a fund of support to independent projects (4). 
Before the creation of  UIC, the IPOP had already established partnerships not only with 
important national and international biopharmaceutical industry and also with academic 
institutes that performed clinical trials and promoted the investment in clinical research in 
general, contributing also to support the independent investigators of own trials (4). The 
European Organisation for Research and Treatment of Cancer (EORTC) is an example as 
well as several cooperative groups, such as: Lung Cancer Group, Digestive Portuguese 
Group and Breast Cancer Group (4), (MS p.c.). 
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Figure 5: The Organigram of UIC [adapted from(1)]. 
The Administrative and the Operational Assistants assist all team members but are under the purview of the Operational Manager. 
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1.2 Training Objectives 
During my Biomedical Sciences Degree and Master´s Course in Pharmaceutical Medicine, in 
University of Aveiro I acquired learning tools and knowledge which, together with my 
expectations about the work of a SC, allowed establishing my primary and secondary training 
objectives. The host institution, the UIC of IPOP, also had influence in the objective’s 
definition. 
Thus, through my curricular internship, I intended to adjust my work in order to achieve the 
following objectives: 
1.2.1 Primary Objectives 
o To gather skills, experience and know-how in clinical studies coordination; 
o To understand  the procedures associated  to the operation of a clinical research centre; 
o To gain experience and expertise in oncology clinical research; 
o To consolidate and apply on the job the knowledge acquired during the Biomedical 
Sciences Degree and the first year of Master´s Course in Pharmaceutical Medicine. 
1.2.2 Secondary Objectives 
o To participate and gather comprehensive understanding in all coordination phases of a 
oncology clinical study; 
o To deepen my understanding in oncology clinical research protocols; 
o To acquire autonomy to perform the activities associated with clinical trials and 
observational studies coordination;  
o To develop interpersonal skills that contribute to a  good professional  performance in the 
clinical studies coordination – assertiveness, proactivity, working in a multidisciplinary 
team and problem solving; 
o To establish a professional contact network, cooperating with distinct professionals like 
physicians, study nurses, pharmacists, Clinical Research Associate (CRA), and other 
professionals whose activities are daily or frequently associated with the SC in the clinical 
studies conduction; 
o To contribute to the improvement of clinical research in UIC. 
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1.3 State-of-the-art of the Clinical Research 
Clinical research is the investigation with human subjects that is (15):  
o Patient-oriented research: It is performed in human subjects (or on material of human 
origin such as tissues, specimens, and cognitive phenomena) (15, 16). It involves a direct 
interaction between the human subject and the investigator (15, 16). It may include 
mechanisms of human disease, therapeutic interventions, clinical trials or development of 
new technologies (15, 16); 
o .Epidemiological and behavioural studies: They enable to assess distribution of disease, 
factors that affect health, and how people make health-related decisions (15, 16);  
o Outcomes research and health services research: They seek to identify the most effective 
and most efficient interventions, treatments, and services (15, 16).  
Results from clinical research are used to decide the diagnostic, to treat or make a 
prognostic of pathologies (17). In addition, the conduction of clinical research in humans 
includes strict scientific guidelines and legal and ethical principles to protect the volunteers. 
The activities related with clinical trials are conducted in a trial site. This site may be a public 
or private institution, a laboratory or other entity with adequate human and material resources 
to conduct a clinical trial in national territory or other Member State (MS). In my opinion it 
seems important to have a structured, qualified and trained team, including GCP managers, 
operational managers, healthcare professionals, SCs, technical assistants, among others to 
improve the performance of clinical trials activities and consequently improve the 
effectiveness, safety and quality of clinical research.   
Only through clinical research, it is possible to gain insights and answers about the safety 
and effectiveness of treatments. It is important to recognise that scientific advances in this 
area was possible only due to the participation of volunteers, both healthy and those 
diagnosed with an illness. Therefore, clinical research requires complex and accurate testing 
in collaboration with communities affected by the disease (18). 
Improving the overall capacity of the clinical research centre will depend on ensuring an 
appropriate infrastructure in place to support the investigators, volunteers and institutions 
that organised and carry out the trials (19).  
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1.3.1 Overview of the Global Pharmaceutical Research & Development 
Pharmaceutical R&D is the process of discovering, developing and launching new drugs to 
the market.  The discovery process comprises all early research to find a new drug candidate 
and testing it in the lab (20). At the end, researchers expect to have a promising candidate 
drug to test in humans (20).  During the development process, the candidate drug must 
undergo extensive studies in humans and must prove to be safe and effective before it is 
approved by regulatory entities (20). This process involves conducting clinical trials with 
specific goals and requirements and it is organised into distinct phases that will be addressed 
in more detail, in the section 1.3.2 “Clinical Trials Classification”.   
The research-based biopharmaceutical industry has provided a crucial contribution to the 
European health and economy (21). For decades, the R&D process has led to the increase 
of the number of new drugs that have been approved and marketed (21). The increase in 
R&D of new drugs has coincided with the constant growth of biopharmaceutical industry in 
Europe through augment in productivity, contributing to the Europe’s balance of trade and 
employability (21).   
However, currently, the R&D process is facing some difficulties (21). Global R&D expenditure 
in the pharmaceuticals and biotechnology sector has steadily increased, without a 
corresponding output in new medicines that reach the market and the patients, as it is 
represented in the figure 6 (21). The number of new drugs defined by the new chemical 
entities (NCEs), approved by year, has not kept pace with the R&D costs (21). According to 
the data of figure 6, despite the progressive increase of R&D costs, the number of NCEs 
approved has decreased extensively between 1995 and 2004 (21).  Currently, this trend has 
remained and became unsustainable (22). 
The R&D of a new drug is a long, resource-intensive and complex process. According to the 
estimates, the costs to bring a new molecule to the market are around €292 million ($400 
million) and €658 million ($900 million) between the period 1994 to 2000. The current trend 
has been a significant raise in this value (5, 21).  
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Furthermore, despite of the long time to the R&D of a new drug (10-15 years), there is a high 
possibility that this drug will fail to reach the market (5, 20). This is the major reason for 
concern, also identified, as a bottleneck. Data about attrition rates indicates that the 
probability of a drug candidate passing from pre-clinical stages (the first stage of laboratory 
study on toxicity) to market commercialization is 6% or less (5, 20).  The reasons to the 
failure of R&D process are the lack of efficacy (25%), clinical safety concerns (12%) and 
toxicological findings in pre-clinical evaluation (20%) (5).  
Currently, European clinical research is facing some challenges  related with  escalating and 
unsustainable drug development costs, high failure rates, pharmaceutical R&D is moving out 
of Europe, public spending on health R&D is a fraction and is stagnating compared to the 
USA, private sector spending on R&D is becoming increasingly spent in the United States of 
America (USA), and is increasing risk adversity among investors (21). Therefore, scientific 
breakthroughs are not translated into the expected results, and research efforts are 
fragmented (21). In this context, it is important to  recognise the phenomenon of clinical trials 
globalisation and its implications to the pharmaceutical R&D over the world (23). Clinical 
trials are moving out of developed countries in regions like Western Europe and USA to be 
conducted in developing countries such as Eastern Europe, India, South America, and China 
(23). A reason behind the globalisation is cost savings due to lower salaries of physicians, 
Figure 6: Global R&D expenditure, Development times  versus New Chemical Entities 
(NCEs) approved (1995-2004) [adapted from(5)]. 
The more recent data is not entitled to free access. 
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nurses and SCs in emerging countries. In addition, clinical trials in emerging countries are 
attractive due to the high population sample (“large pool of potential research participants”) 
that ensures an accelerated recruitment rate, simplified and cheaper regulatory environment, 
foster positive relationships among investigators and answer questions of concern 
throughout the world (23). This will contribute to increase the returns invested in 
pharmaceutical R&D (23). In this way, it is crucial to streamline regulations in order to reduce 
redundancy while ensuring ethical conduct (23).  
In order to bridge the bottlenecks in the R&D process of new medicines, two international 
initiatives have been developed to revolutionise the conventional drug development 
paradigm and support the faster discover and development of better and innovative 
medicines (5). These initiatives are Critical Path Initiative (CPI), from USA and Innovative 
Medicine Initiative (IMI) from Europe. 
“The CPI is a strategy of Food and Drug Administration (FDA) to drive innovation in the 
scientific processes through which medical products are developed, evaluated, and 
manufactured” (24). This initiative was intended to highlight the need for collaborative efforts 
of all stakeholders (federal agencies, patient groups, academic researchers, industry, 
healthcare practitioners, and others) in order to increase the efficiency, predictability, and 
productivity in the development of new medical products (5). Thus, CPI is based in 6 topics 
that address specific tools, techniques and methods to improve the candidate drug’s 
performance. The topics are synthesised in the table 1 (24, 25).  
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Table 1: Brief description about CPI topics [adapted from (25)].  
Topic Description 
 
 
Biomarkers development 
Biomarkers would improve the efficiency of product 
development; help identify safety problems before a 
product is on the market. They can reduce uncertainty by 
providing quantitative predictions about performance and 
also can revolutionize product development for a disease 
group. 
 
 
Streamlining clinical trials 
To improve the design and conduct of a clinical trial to 
increase the efficiency of product development.  These 
trials define and measures the variations in individual 
responses Personalized Medicine. 
 
 
Bioinformatics 
An application that permits analyse biological data about 
patients, with the goals of creating robust, quantitative 
computer models of normal human physiology, of the 
natural human history of certain diseases and of the 
course of a disease affected by standard treatments. 
 
Manufacturing Tools that help to identify and to analyze critical products 
to improve efficiency and quality in manufacturing. 
 
Antibodies and 
countermeasures to combat 
infections and bioterrorism 
 
Methods that help rapid pathogen identification and 
better predictive disease models. 
 
Developing therapies for 
children and adolescents 
To improve methods for predicting if treatments will work 
in children and adolescents are combined and analyse 
data from existing paediatric studies. 
The IMI results of collaboration of public and private sector between large and small 
biopharmaceutical, healthcare companies, regulators, academia and patients (5). The IMI 
proposes paths to the faster discovery and development of more effective innovative 
medicines with fewer side-effects enhancing Europe’s competitiveness. This initiative 
establishes 4 pillars that address the bottlenecks in the current R&D process (5). The topics 
are presented in the table 2 (5). 
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Table 2: A brief description about the pillars of IMI [adapted from (5)]. 
Pillar Description 
 Predictivity of Safety 
Evaluation 
 9 recommendations to improve the predictivity in safety 
evaluation and benefit - risk assessment with regulatory 
authorities. 
 
 Predictivity of Efficacy 
Evaluation 
9 recommendations to improve the predictivity 
pharmacology, the identification and validation of 
biomarkers, patient recruitment and benefit - risk 
assessment with regulatory authorities. 
 
 Knowledge Management 15 recommendations including the establishment of a 
Translational Knowledge Management and the creation of 
a Knowledge Management Platform to break the 
bottlenecks related to gaps in information technologies. 
 
 Education  and Training 5 recommendations addressing the bottlenecks related to 
gaps in expertise in biomedical R&D knowledge and skills. 
Implementation of multidisciplinary programmes to 
develop skills. 
 
Recently, on 10 July 2013, the European Commission (EC)  released its proposal for the IMI 
2 that it is expected to start in 2014 (26). The IMI2 addresses the major challenges currently 
facing the European healthcare system, the pharmaceutical industry and the regulatory 
framework together with research required to attend them (26). “The aim of IMI2 is to enable 
an appropriate European-level research and innovation response that will make a crucial 
contribution to delivering better health and wellbeing for all, and positioning Europe as a 
leader in the rapidly expanding global markets for health and wellbeing innovations” (26). 
The vision of IMI 2 is to deliver the right treatment to the right patient at the right time for 
priority diseases, supporting the personalised medicine and prevention (26).IMI 2 will drive a 
new and integrated approach on R&D that it will be concretised through the cooperation 
between all sectors within the healthcare ecosystem (26). Thus, IMI2 focus the creation of 
new biomedical public private partnerships between the pharmaceutical industry and the 
European Union (EU) (represented by the EC) that will facilitate the engagement and 
coordinated co-operation between all key stakeholders in the provision of healthcare today 
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such as healthcare practitioners, regulators, patients and payers to ensure new scientific 
advances are translated into innovative, effective products, strategies, interventions and 
services (26). 
1.3.2 Clinical Trials Classification 
According to the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Topic E6 (R1) – Guideline for GCP, a 
clinical trial or clinical study is defined as “Any investigation in human subjects intended to 
discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an 
investigational product(s), and/or to identify any adverse reactions to an investigational 
product(s), and/or to study absorption, distribution, metabolism, and excretion of an 
investigational product(s) with the object of ascertaining its safety and/or efficacy” (27). 
Clinical trials are commonly classified into 4 temporal phases (Phase I-IV). However, the 
temporal phases do not imply a fixed order of studies. Thus, it is preferable the classification 
based on study objectives: human pharmacology, therapeutic exploratory, therapeutic 
confirmatory and therapeutic use. The clinical trials classification consists of (28):  
o Human Pharmacology:  Typically these studies are associated with phase I and they start 
with the first administration of  investigational product (IP) in humans with non-therapeutic 
objectives, including initial safety and tolerance assessment, pharmacokinetic and 
pharmacodynamic definition, and drug metabolism and drug interactions determination 
(28). Usually, these studies are conducted in a small population of healthy volunteers (20-
100), except in case of drugs with potential toxicity, that are carried out in patients (28).  
o Therapeutic Exploratory:  Typically these studies are associated with phase II and they 
are conducted in a group of patients (100-500 patients, selected by moderately narrow 
criteria which leads to homogeneous population) with the disease under study to 
investigate the therapeutic efficacy (28). Another goal is to determine the dose and 
regimen for subsequent studies (phase III) (28). Additional objectives are to evaluate 
potential endpoints, target population and methodologies for confirmatory studies (28). 
o Therapeutic Confirmatory: Typically these studies are associated with phase III and they 
are conducted in a larger patient population (1000-5000) to demonstrate or confirm 
therapeutic benefit (28). These studies are intended to confirm the evidence accumulated 
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during phase II (safety and effectiveness to the evaluation of overall benefit-risk profile of 
the treatment) and provide a basis for marketing approval (28). 
o Therapeutic Use: Typically phase IV Studies are conducted after the drug approval - after 
demonstration of the drug’s safety, efficacy and dose definition - and are related to the 
approval indication. They are not required for approval, but are intended to optimise the 
drug’s use (28, 29).  
1.3.3 Current Situation of Clinical Trials in Portugal 
The presence of regulatory framework in Portugal includes both an EC directive and 
Portuguese legislation. Therefore, in Portugal, the conduction of clinical trials on medicinal 
products for human use according to the GCP  is governed by the legal regime established 
by Law nº 46/2004, of August 19th, which is transposed into the national law through the 
Directive nº 2001/20/EC of 4 April 2001 of the European Parliament and of the Council  (30). 
The regulation of these aspects in a harmonised way through international (ICH) and 
community level ensures the integration by guidelines and quality requirements that govern 
the conduction of clinical trials (30). The main goal is to protect the subjects who participate 
in the research. Recently, the legislation is compiled in the volume 10 (The rules governing 
medicinal products in the European Union) of EudraLex (30, 31). 
Clinical research in Portugal has been losing its position in the context of global investment in 
health (4). 
Since 2006, the number of clinical trials submitted and authorised has been steadily 
declining. The lowest value was reached in 2011, with 88 studies (4). Phase III clinical trials 
have a great expression in Portugal and represent about 68% of clinical trials number 
approved in 2012 (4). The completion of phase I clinical trials is almost null, only 8 studies 
were authorised over the last 4 years (4). According to the data of INFARMED the 
predominance of treatments covered by authorised clinical trials corresponds to the 
antineoplastic and immunomodulating agents, anti-infectious agents and central nervous 
system agents (32). The number of new patients enrolled has been declining, with exception 
in 2011 (4). The study “Ensaios Clínicos em Portugal (Potencial de Investimento)”, 
conducted by “Associação Portuguesa da Indústria Farmacêutica” (APIFARMA) concluded 
that, between 2007 and 2011, It was only 70% of patients initially planned were recruited (4).  
The average approval times of a clinical trial exceed 70 days between 2009 and 2011 (4). 
This time does not include the approval by administration of the trial site which is essential to 
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start the study and can take several months. The regulatory entities responsible to the 
clinical trial approval process are “Autoridade Nacional do Medicamento e Produtos de 
Saúde I.P” (INFARMED) that authorises the conduction of clinical trial (4, 33); “Comissão de 
Ética para a Investigação Clínica” (CEIC) which provides an opinion in to conduct the clinical 
trial and “Comissão Nacional de Proteção de Dados” (CNPD) that authorises the health data 
processing performed in the context of the clinical trial (4, 34, 35).  
In Portugal, the majority of clinical trials is promoted by multinational pharmaceutical 
companies (4). The Investigator-driven clinical trials (IDCTs) are scarce when compared with 
other European countries, like Spain and United Kingdom(4) .  
In this way, clinical research in Portugal is facing barriers which have contributed to the loss 
of country’s competitiveness in attracting these activities (4). In 2013, APIFARMA 
summarised these barriers (4) namely: 
o Policy and Strategy of the sector: The clinical research activities are not recognised as 
strategies to the improvement of health care neither to the national economy. There is no  
development strategy due to the lack of adaptation of the regulatory framework to the 
requirements of activities such as,  inefficient funding mechanism, incentives to improve 
the trial sites conditions, creation of  research networks and promotion of independent 
research. Additionally, there is a negative reputation of clinical trials. 
o Regulation and Legislation: The time required for clinical trials approval is long and usually 
exceed the statutory period of 60 days for application approval by regulatory entities, 
referred above. The financial contracts do not follow a standardised structure and its 
approval by hospital administrations is also a lengthy process and it can take several 
months. There is not defined specific legislation to the public disclosure of clinical trials. In 
addition, the volume of clinical trials promoted by investigators, IDCTs, is greatly reduced, 
due to the lack of a legal framework that regulates and promotes this initiative. 
o Organisation and Infrastructures: Hospital administrations do not recognise the potential 
strategic of clinical research. There is a lack of appropriate infrastructures that drives to 
the inefficiency of centre as well as a poor cooperation between key stakeholders. 
o Incentives, Training and Career: The failure in financial incentives diminishes the 
availability of professionals to participate in clinical trials activities that are not valued for 
the purposes of career advancement. The academic degree in health care area not 
provides a deep basis in clinical research. Additionally, there are no full conditions, such 
as financial systems, partnerships and support to promote and perform IDCTs. 
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o Technology and Information: Despite of the “Plataforma Nacional de Ensaios Clínicos” 
creation, the information access about clinical trials is very limited, scattered and hamper 
the interaction between different stakeholders.  
Therefore, the success of clinical research in Portugal will depend on the definition, and 
implementation of initiatives in order to overcome the obstacles referred above, as well as, 
the recognition of clinical research potential to Portugal (4). Examples of initiatives are: 
review of current legislation on the clinical trials approval process and review of funding 
programs and incentive systems for clinical research (4). Currently, the regulatory framework 
for clinical trials in Portugal is undergoing a revision. There is a proposal for a regulation of 
European Parliament and of the Council on clinical trials on medicinal products for human 
use that repeals the Directive nº 2001/20/EC (36). The reasons for this proposal are related 
to the unsatisfactory results of clinical research during the last years (36). Thus, this new 
proposal addresses these results and barriers in order to combat them and improve the 
clinical research. Despite of this scenario, the IPOP is an institution engaged in promoting 
and fostering the activity of clinical trials in Portugal (4, 13). According to the data of figures 2 
and 3 since its creation, the UIC of IPOP assumed a progressive and sustained growth at 
different levels (4). This activity has been an opportunity to the patients, ensuring the access 
to the innovative treatments with potential beneficial health effects (4). 
1.3.4 Current Trends in Clinical Oncology Research 
Recent data from the EU (27 countries) point that in 2008, 2.5 million people were diagnosed 
with cancer that is the second most common cause of death (29% of deaths for men or 3 out 
of 10 deaths, 23% for women or 2 out of 10 deaths) (37). This scenario is expected to 
increase due to the aging population (37).  
The most common types of cancers in the EU were colorectal, breast (most common in 
women), lung (most common in men) and prostate cancers (37).  
Despite progress over the past 10 years, cancer remains a key public health concern and a 
huge burden on European societies (5). The treatment of several cancers is inadequate and 
it is urgent to improve all aspects of the cancer research, from prevention to translational and 
clinical research (5). The main problem of cancer treatment is the lack of quality systemic 
treatments (5).   
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Currently, almost half of the NCEs in clinical development are directed against cancer 
targets, like bevacizumab, cetuximab and trastuzumab (5). In addition to the high-risk of 
these plans, there is lack of disease-related biomarkers to sustain early decision-making on 
products (5). The IMI emphasise the need of collaboration in cancer research, and its 
success “is dependent on close working relationships with major cancer organisations such 
as the EORTC, other national cancer bodies and the major cancer charities” (5). The 
ambitious goal established by Commission Communication on Action Against Cancer: 
European Partnership is to reduce the cancer incidence by 15% until 2020 (5, 37). 
In this context, in Portugal the majority of clinical trials are promoted by multinational 
pharmaceutical companies of R&D and the main area of health involved is the oncology 
representing 40% of the total (4, 38).  
Recently, it was initiated the clinical trials with the first Portuguese drug for oncologic patients 
(39). The action mechanism of this oncology treatment is based on the photodynamic 
therapy, a form of treatment of the tumours, cancers and other deformations of the tissue, 
using light and photochromic compounds in combination with the oxygen contained in the 
tissue (39). LUZ11 is the code name of the Portuguese drug for treatment of cancer (39). 
This is a good example to strengthen the clinical research in Portugal, in the oncology field. 
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2. Generic Training 
At the beginning of my internship, I performed the ICH/CGP online training course and 
acquired the certificate in GCP.  This training was organised into different modules and at the 
end of each module, I answered to some questions related with the content of the respective 
module. After to the course modules completion, there was a final assessment which 
consists of a reasonable number of multiple choice questions in order to evaluate the 
learning level acquired during the course. This course is an essential resource required to 
conduct all activities related to the clinical trials. In addition to this course, I also performed 
online training courses on Electronic Data Capture systems, namely in Medidata Rave®, 
InForm TM and Oracle® Clinical Remote Data Capture Onsite”. The table 3 presents a brief 
description of each Electronic Data Capture system. 
 
Table 3:  Brief description of Electronic Data Capture systems used during the internship (40-
42). 
System Description 
 
Medidata Rave® 
Web tool for capturing, managing and reporting clinical 
research data, designed by efficiently streamlining the clinical 
trial process (41).  
 
InForm 
TM
 
 
Internet-based tool selected for use on clinical trials to enter 
clinical data into the electronic case report forms (eCRFs) (40). 
 
Oracle® Clinical Remote 
Data Capture Onsite 
Web application that works with studies defined and designed 
using Oracle Clinical platform. RDC Onsite is used to collect, 
review, and report clinical data collected during a patient visit in 
a clinical study (42). 
 
These courses had a similar structure to the ICH/GCP course. They were divided into distinct 
modules with intermediate assessments at the end of each module, and a final assessment. 
The courses completion was an essential support tool to the introduction of clinical data in 
Case Report Form (CRF). Consequently, this is one of the many activities of a SC that will be 
addressed, in more detail, in the next section. 
Additionally, it was required to acquaint me about theoretical tools in order to support my 
clinical trial coordination activities in the context of the oncology clinical trials protocols. Its 
knowledge was essential to understand, organise and execute activities, procedure and 
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tasks regarding the clinical trial protocol. These tools are the Eastern Cooperative Oncology 
Group (ECOG) Performance Status, the Common Terminology Criteria for Adverse Events 
(CTCAE) code and the Response Evaluation Criteria In Solid Tumours (RECIST) criteria and 
the Cancer Staging. 
ECOG Performance Status (see table 4) is a scale and criteria used by physicians to 
evaluate the disease status of patients (if it exists progression), by the level though which 
disease is affecting the daily living activities of the patient (43).  
Table 4: The ECOG Performance Status (43). 
 
 
 
 
 
 
 
The CTCAE code is a descriptive terminology used for Adverse Event (AE) reporting (44). 
There are two different and main CTCAE codes used for classification of AE: the version 3.1 
and actually the version 4. Each clinical trial protocol defines the version for AEs 
classification. For each AE term is provided a grade that refers to the severity of the AE (see 
table 5) (44). 
 
 
 
 
 
Grade Description 
0 Fully active, able to carry on all pre-disease performance without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work. 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours. 
3 Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours. 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or 
chair. 
5 Dead 
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Table 5: Description of AE Grades [adapted from (44)]. 
Grade Severity 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2 Moderate; minimal, local or non-invasive intervention indicated; limiting age-
appropriate instrumental Activities of Daily Living. 
3 Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self care Activities of Daily Living. 
4 Life-threatening consequences; urgent intervention indicated. 
5 Death related to AE. 
The RECIST criteria are a set of rules that define the response of cancer patients to the 
treatment. Thus, it is possible to assess when patient improves ("responds"), stays the same 
("stable”) or worsens ("progression") (45).  
The Cancer Staging describes the severity of the same in a patient according to the size 
and/or extent of the original tumour, and whether cancer has spread in the body (46). The 
common elements considered in the majority of staging systems are (46):  site of the primary 
and the cell type - corresponds to the cells kinds found in cancer tissue; tumour size and/or 
extent (reach);  regional lymph node involvement - the spread of cancer to nearby lymph 
node;  number of tumours - the primary tumour and the presence of metastatic tumours, or 
metastases; tumour grade - how closely the cancer cells and tissue resemble normal cells 
and tissue. 
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3. Specific Training 
3.1 Clinical Trials Coordination 
Clinical trial coordination involves a vast number of activities and processes. The SC has a 
critical role in the clinical trial implementation, supporting the clinical trial team in every 
activity related to the preparation and organisation of the procedures and documentation.  
As IPOP is structured by clinics such as: Urology, Gynaecology, Digestive, Lung, Soft Tissue 
and Skin, Head and Neck, Onco-Haematology, Breast, Paediatry, Endocrine Tumours, 
Nervous System, the several clinical trials are worked on these clinics (47). During my 
internship, I participated in phase II clinical trials in digestive, lung and soft tissue and skin 
pathologies and several phase III clinical trials as presented in table 6. 
Table 6: Clinical trial phases and number according to the  clinics of pathology in which I was 
enrolled (48).  
The list is available online. 
Clinics of Pathology Number of Clinical Trials per 
Clinics of Pathology and Phase 
 Phase II Phase III 
Urology -- 4 
Gynaecology -- 4 
Digestive 2 1 
Lung 1 2 
Soft Tissue and Skin 2 -- 
Head and Neck -- 2 
Onco-Haematology -- 10 
Breast -- 2 
Paediatry        11 -- 
 
1
 Phase IIb  
I will present the clinical trial coordination activities according to the stage of clinical trial - 
initiation, conduction and closeout of a clinical trial. I performed the conduction activities in all 
clinics of pathology and an initiation activity in the Onco-Heamatology clinic. Then, in the 
table 7, it is summarised the specific tasks (according to the stage of clinical trial) executed in 
each protocol regarding the clinic of pathology. Finally, it is described in detail the experience 
that I gained during my internship. 
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Table 7: Synthesis of Clinical Trials Coordination Activities and Tasks performed in each Clinic of Pathology
 
Clinical Trial Coordination Activities 
and Tasks 
Clinical Trial Coordination Tasks versus Clinic of Pathology 
 
Urology Gynaecology Digestive Lung Soft Tissue 
and Skin 
Head and 
Neck 
Onco-
Haematology 
Breast Paediatry 
Initiation  
 
Initiation visit 
 
-- -- -- -- -- --  
X 
-- -- 
Conduction  
Recruitment Period: -- -- X X -- -- -- -- -- 
Screening; -- -- X X -- -- -- -- -- 
Randomisation of patients; -- -- X X -- -- -- -- -- 
Clinic Visits: X X X X -- -- -- -- -- 
Schedule of visits; X X X X X X X X X 
Preparation of Visits; X X X X X X X X X 
Patient’s visit; X X X X X X X X X 
Documents, CRFs and AEs Report; X X X X -- -- -- X -- 
Packaging and Sending biological 
samples;  
X -- X X X -- -- -- -- 
Other activities performed after the 
visits; 
X X X X X X X -- X 
Patient’s Discontinuation; -- X X X -- -- -- -- -- 
Monitoring visits X X X X -- -- -- -- -- 
Emergency Code Break X -- -- -- -- -- -- -- -- 
Closeout  
--- -- -- -- -- -- -- -- -- -- 
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3.2  Clinical Trial Initiation Activities 
Next, I will present the initial activities and procedures that involve a clinical trial, namely, the 
signature of a confidential agreement, assessment of the site conditions through the 
completion of the feasibility questionnaire, pre-trial qualification visits, analysis of financial 
contracts, clinical trial approval, investigator meeting an the clinical trial initiation visit to 
prepare the site to conduct the study. 
3.2.1 Assessment of new Clinical Trials and Pre-Trial Visits  
The sponsor or Contract Research Organisation (CRO) delegated is responsible for selecting 
the suitable sites to conduct the clinical trial (27). In the IPOP, the study is proposed directly 
to the UIC (MS p.c.). The UIC acknowledges the study to two elements: the director of the 
clinical service where the study is going to be performed and the clinic pathology director that 
will appoint the principal investigator (PI) and will lead the recruitment plan (MS p.c.).  
The initial preparation of a new clinical trial involved the signing of a confidentiality 
agreement. 
o Signature of Confidentiality Agreement: Confidentiality agreement or non-disclosure 
agreement is ensures the confidentiality of information and it is established between the 
PI and CRAs of the study. The agreement is signed to guarantee that both parties agree 
with the information addressed in the document (49). The operational manager of the 
institution is responsible to send the signed and dated confidentiality agreement by PI to 
the CRA (MS p.c.).  
o Assessment of the site conditions: The assessment of site conditions may be done 
through the conduction of pre-trial visits and completion of the feasibility questionnaire. 
o Pre-trial Visits: The purposes of these visits are to review the site adequacy, the training 
and experience of the study staff, the access to target patient population, and the site’s 
interest in the clinical trial (MS p.c.). In IPOP, the representatives appointed by sponsor 
are to evaluate the site conditions are accompanied by the coordinator of UIC, the 
manager of GCP and quality, the operational manager and by investigator (MS p.c.). 
o Feasibility Questionnaire: The feasibility questionnaire is an assessment tool that contains 
a specific questionnaire of the study to determine the incompatibility or viability of 
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promotion or implementation of the same in the site (50). This questionnaire enables to 
obtain the data about the target disease, potential for patients’ recruitment, infrastructures 
and facilities of the site and also regarding human and material resources (50). In IPOP, 
the professional responsible to answer to this questionnaire is completed by the service 
director, the clinic pathology coordinator or the appointed PI. It must exist an 
understanding between these 3 intervenients (MS p.c.). 
o Financial Contracts Analysis (review and signature): The financial contract must be 
reviewed and signed. This document sets the terms of clinical trial completion, the 
conditions of its provision and the economic aspects to be agreed between the sponsor 
and site (49). This contract contains direct and indirect costs of study, the payment period 
and all conditions established between the parties (49). The IPOP uses own template with 
payment percentages to the research team members. In UIC, the manager of GCP and 
quality is responsible to discuss and review the main points of document with CRA (MS 
p.c.). After reaching an agreement, it is submitted to the IPOP Administration Board (AB) 
and CEIC (MS p.c.). 
o Clinical trial Approval: According to the ICH-GCP (27) and the Portuguese legislation (Law 
nº 46/2004, of August 19th) (51) , the conduction of a clinical trial requires a prior approval 
of INFARMED, CEIC and CNPD. After the study approval by regulatory authorities, the 
preparation of clinical trial submission to the IPOP AB (MS p.c.). The submission file 
involves the compilation of several documents and signatures, such as: curriculum vitae 
(CV) of the PI; financial contract signed and dated by the sponsor/CRO and PI (MS p.c.). 
CV identification of the sponsor, study synopsis, study protocol, investigator brochure, 
informed consent, insurance certificate, clinical agreement and study authorisation by 
service director, study approval by regulatory authorities and materials to be used during 
the study are included in the submission dossier (MS p.c.). After a last review of the 
dossier sent by the sponsor/CRO and by the manager of GCP, the approval is sent to the 
operational manager (MS p.c.). This team member is responsible for gathering the internal 
approval of the financial manager and a letter of accordance of the medical coordinator of 
UIC (MS p.c.). Then, the dossier will be sent to the IPOP AB for final approval (MS p.c.). 
Thus, the implementation of clinical trial in the institution depends on the final and 
favourable opinion of AB (MS p.c.).  
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During my internship, I did not have the opportunity to actively participate in all these 
activities. However, I am acquainted with the same because I had an oral session, in which, 
it was explained to me the following topics:  
 What is involved in each of these activities; 
 The order in which they occur; 
 The professionals of the institution which collaborate in these activities; 
 Some particularities applied to the institution. 
 This explanation allowed was important to consolidate the sequence of activities and 
what activities are performed to get the clinical trial approval. 
3.2.2 Investigator’s Meeting 
An investigator´s meeting is a meeting organised by the clinical trial sponsor, or its 
representatives and attended by investigators and site personnel who have agreed to 
participate in the multi-centre clinical trial (52). In this working session the investigators are 
informed about the pharmacology of the investigational medicinal product and it is provided 
updated clinical information of compound (52). The main purpose is to ensure the 
understanding of the protocol, study design and other clinical trial procedures, as well as to 
foment consistency in protocol compliance and clinical trial procedures among sites. In 
addition, this meeting is also important because (52): 
 It ensures that everyone involved in study receives the same information; 
 It enables training in therapeutic area and specific review of the protocol and 
associated documents, like eCRFs; 
 It provides to the site personnel - that in the UIC may involves, the investigators, 
operational manager and SCs – the opportunity to discuss study logistics and to meet 
key sponsor (CRA’s, project managers, medical officers, among others).  
During my internship, I did not have the opportunity to participate in an investigator´s 
meeting. In despite of this, I received the feedback of UIC team members that already 
participate in several meetings. They explained me about the specific contents covered in 
these sessions (eligibility criteria, recruitment, safety concerns) and emphasised the 
opportunity to clarify doubts related to the protocol and establish professional relationships. 
In addition, they also sensitised me to the SCs participation in these sessions because the 
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knowledge acquired will contribute to conduct the study activities with more accuracy and 
security.  
All these steps described were explained to me by my supervisor in a formal meeting. 
However, I did not the opportunity to perform or accompany them, perhaps because of the 
level of specialisation of tasks at UIC in IPOP. 
3.2.3  Clinical Trial Initiation Visit 
Clinical trial initiation visit is required to prepare and set up the site to conduct the study.  The 
main purpose of this visit is to ensure that clinical trials will be conducted under the suitable 
conditions. This visit involves a meeting with investigators, SC, pharmacists, study nurses 
among other elements of research team. It is conducted by a sponsor representative, usually 
a CRA. During the internship I had the opportunity to attend an initiation visit and follow the 
procedures before, during and after the visit. This visit occurred in the ambit of a clinical trial 
of Onco-Haematology clinic. 
The first step before the visit was to schedule an appropriate date, time and place with CRA 
and research team. Until the visit date, some essential documents were being prepared, 
obtained and filed. These documents included the CVs of research team and signature of the 
financial disclosure. During this time, some study trainings were completed by research team 
members and the certificates were filed. In addition, I tried to understand the key aspects 
related to the protocol and I read the protocol synopsis. 
In this visit, the CRA initiated its presentation after confirming the presence of expected 
research team in the room. Throughout the meeting, the CRA review the following items (27, 
53):  
 Study protocol: objectives and study design, study-specific procedures and skill sets 
(imaging schedule and modalities, electrocardiogram (ECG) time points), inclusion and 
exclusion criteria, recruitment (strategies and targets) and timelines, protocol 
amendments; 
 Investigational Product: dispensing, preparation, administration and unblinded 
procedures; 
 Laboratory Procedures: supplies (central lab kits, manuals, shipping materials, patient 
folders), sample collection, processing and shipping requirements and central 
laboratory considerations (transmission of lab results); 
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 Records: screening and recruitment logs, drug accountability and dispensing logs; 
 Data Collection:  eCRFs; 
 Safety Reporting: Serious Adverse Event (SAE) and AE; 
 Training: It was specified the training needs of research team members and 
addressed, if required, the hypothesis of additional training prior to initiate the study. 
During and after the presentation, the research team had the opportunity to discuss these 
items and also clarify relevant doubts related to the study. At the end of presentation, SC 
delivered some documents to be signed by team members such as, delegation signature log 
and visit log, among other essential documents. 
 After conclusion of these procedures, the visit took place in UIC, only between SC and CRA. 
The purpose was to provide relevant study supplies, check the organisation of clinical trial 
materials operational equipment (electrocardiographs) in UIC and organise the documents in 
the Investigator Site File (ISF).  The study supplies provided were the electrocardiographs 
(including training CD and manual), imagiology manuals, patient cards, study medication 
diaries and administrative binders. The SC was informed about the randomization, 
medication assignment, completion study medication diaries, SAE and AE reporting 
procedures, CRFs and source documents. Then, the CRA provided the way to create the 
passwords for eCRF and Interactive Web Response System (IWRS). This password belongs 
to the respective SC and cannot be shared. 
Furthermore, the CRA was also to the clinical trials pharmacy to supply some materials and 
train the professionals. CRA was also in the local lab with study nurse to supply the central 
lab kits, manuals, shipping materials, patient folders and to clarify some sample collection 
procedures.  This visit can be performed in one or more days. The sponsor/CRO schedules 
the visit with team members required in order to train properly the team members. After this 
visit completion, the site is ready to initiate recruitment strategies and begin enrolling 
patients.  
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3.3 Clinical Trial Conduction Activities 
3.3.1 Recruitment Period 
During this period, the investigators have the opportunity to recruit the patients for the study 
(49). The expected number of patients to include in the study and recruitment timeline is 
specified in the initiation visit. 
 During my internship, my contribution to the patient recruitment was through the consultation 
of clinical processes of patients which had been recently admitted in a clinic of pathology of 
the IPOP. Thus, together with other SC, I read the clinical data of patients and checked, 
according to the eligibility criteria, if patient met any inclusion and/or exclusion criteria. When 
I found a patient that met one or more inclusion criteria and no exclusion criteria, I warned 
the responsible SC and this patient was signalised. Throughout this process, I only analysed 
the inclusion and exclusion criteria that I was able to understand. All these criteria are then 
verified by the PI or sub-investigator in order to recruit the patient. 
The majority of contribution to the patient’s recruitment is done by PI and co-investigators of 
study during the group consultations, external consultations and emergency service. I did not 
have the opportunity to attend a group consultation (during which it is decided the treatment 
for a patient), however, the SC of UIC may participate and contribute to find eligible patients. 
When an investigator finds a potential patient to include in a study in any external 
consultation or group consultation, he/she contacts with the SC in order to request an 
informed consent. Then, the SC goes to the consultation and delivers the informed consent, 
the main inclusion/exclusion criteria and also the flowchart of events to investigator which 
provides an explanation about the same (emphasising essential aspects related to the 
treatment proposed). After that, the investigator advises the patient to take home the 
document, read it carefully and to identify doubts to be clarified in the next consultation. 
Thus, in the next visit, after the investigator explains and eliminates the patient doubts, it is 
known the patient’s decision. When the patient decides to sign the informed consent, the 
investigator registers the information in clinical process and informs the SC, which is 
responsible to schedule, and ensure that all screening procedures are performed according 
to the protocol requirements.  
o Screening: It is the process in which the investigator identifies the patients to a possible 
inclusion in a clinical trial (49). During my internship, I actively contributed to the schedule 
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of screening procedures. Firstly, I registered the patient in the IWRS or Interactive Voice 
Response System (IVRS) and I get the screening number of patient. This number is a 
crucial datum because it allows the patient identification on the study as well as the three 
initials of the first, second and third name. To access to this system I used the right 
credentials (an user identification and a password). Screening confirmations were sent via 
email or fax. Then, I scheduled all procedures required by protocol respecting the time 
window admitted by the same. The next step was to inform the patients about date and 
cautions before and after performing some exams. 
During this phase, I had special concern to schedule the exams and, consequently, to ensure 
the exam's results, required to randomise the patient, within the timeline required per 
protocol.  
After that, the investigator assessed the exams required to a possible randomisation (in 
another consultation) and checked the eligibility form with inclusion and exclusion criteria. If 
patient meet all criteria, the patient was randomised, if not the patient was considered as a 
screening-failure (SF). It both cases, the investigator register the data in clinical process of 
patient and contact the SC to randomise the patient. The UIC has a patient database that 
allows the unit staff to update and have access of data. When the patient decided to 
participate in a clinical trial, I added the data related to that patient to a recruitment list 
database. The patient status in this document was updated according to the status or 
participation of patient in the study (for example, if the patient was a SF, enrolled, 
discontinued the protocol, withdrew the informed consent, died).  
o Randomization of Patients: It is the allocation method of patient population into groups 
that will receive different interventions which may be test or control groups (49, 54).  This 
method assures that subject populations are similar in test and control groups, minimises 
systematic differences between groups that could affect the outcomes and provides a 
powerful basis for statistical inference (49, 54).  
During my internship, I randomised several patients through the IVRS or IWRS. I had the 
opportunity to use both systems. I used the credentials to access to the platform. Then, I 
introduced all data by the system and at the end, the system assigned to the patient a 
medication number and, in some cases, a patient number (also called randomisation 
number). The system automatically provided real-time confirmation, via fax or email, the 
patient randomisation. After enrolling the patient, I contacted the investigator providing the 
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data about the patient randomised and study treatment, as applicable. This information was 
needed to complete the prescription form by investigator. Then, I wrote a letter (with patient 
identification and treatment assigned), and added the copy of therapeutics order sheet and 
the randomisation confirmation sheet to send (via fax) to the clinical trials pharmacy, where 
the treatment is prepared and dispensed. For example: if the treatment is oral, the 
operational assistants of UIC deliver the medication directly to the patient; if the treatment is 
intravenous, it is administered by study nurses in daily hospital. 
IVRS/IWRS systems were programmed, not only to screening and randomisation, but also to 
register the SFs, obtain subsequent drug assignment or kit re-supply, discontinue a patient, 
acknowledge of study drug receipt, register an unscheduled visit, among others. 
3.3.2 Clinic Visits 
This phase of clinical trials comprised all activities related with patients, including scheduling, 
preparation and conduction of the visits.  
o Schedule of Visits: From the moment that patient is randomised to the protocol, patients 
should comply with the procedures in accordance with periodicity required by protocol.  
These procedures where scheduled by me. After confirming, through an internal electronic 
system of patient management named – “Oásis”, the dial and redial of blood tests (usually 
haematology, biochemistry and urinalysis) consultation and treatment cycle, I called the 
patients. During this call, the information communicated was the following:  
 Date and time of blood tests, consultation and treatment cycle – usually, the blood 
tests and consultation were done in the same day, however, the treatment could be 
done in another day (according to the time window permitted per protocol) due to the 
prolonged treatment time and logistic;  
 Remind the patient to bring the diaries and unused study medication, as well as 
packaging of used medication – concomitant medication (if applicable);  
 Remind the patient to be fasted for biological sample collection; 
 Other procedures: dial and/or redial of scintigraphy, computerised tomography and 
magnetic resonance). 
 In addition to my telephone contact, the administrative of the clinics of pathology sent a letter 
to the patient contemplating all procedures scheduled.  
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The management of patient’s visits/cycles of the several clinical trials was difficult; however, 
the elaboration of a monthly calendar facilitates this task. This calendar was elaborated by all 
SC of UIC. In this calendar, each SC scheduled the patients visits included in its clinical 
trials. In more detail, I introduced the patient initials and the type of visit and/or the number of 
visit (for example, screening, cycle 1, end of treatment, follow-up, observational period) in the 
date that he/she had some procedure. Together with the identification of patient, it was 
identified the study, in which, the patient was participating. When, there was a change in 
calendar, I corrected and warned the trial staff that collaborates in the procedure.  
o Preparation of the Visits: All clinical visits were previously prepared to guarantee 
compliance with all procedures established per protocol. Usually, I prepared the guide of 
visits some 2 or 3 days before the date of visit always in conformity with protocol. This 
guide contemplated a list with all topics needed to record in clinical process of patient by 
investigator. At the end of this guide, I provided the next date of study procedures (usually 
blood tests, consultation and treatment). Together with this guide I added the patient’s 
clinical records, prescription form and other documents (computerised tomography 
request´s, some results of exams already performed).  
o Patient Visits: In the patient's visit day, the preparation of visit (guide of visit and other 
documents) is attached to the clinical process that is sent to the clinic of pathology where 
the patient will be assisted. Before the visit, the patient goes to the local lab and the study 
nurse collects the central samples (these samples are stored, packaged and shipping to 
the central lab) and local blood samples (the parameters of these analysis are essential to 
evaluate the medical condition of patient before taking the treatment) required per 
protocol. During the visit the investigator perform a physical exam to the patient (and 
register the ECOG), lists the concomitant medication and evaluate signs, symptoms, AEs 
and blood tests parameters. If these parameters are compatible with the treatment 
(chemotherapy), it will be administered to the patient. When the blood tests parameters 
are changed but, according to the protocol the dose reducing is allowed, the patient will 
received the treatment but in a lower dose. If these parameters are not compatible with 
the treatment, it will be delayed and scheduled to another date. During the patient visits, 
the investigator contacted me and reported me the clinical status of patient. If the 
treatment was not delayed, I used the IVRS/IWRS system to assign the medication. Then, 
I contacted the investigator and provided the batch number, if applicable, that investigator 
wrote in the prescription form. After that, I wrote a letter (with patient clinical trial 
identification, treatment assigned and batch number, if applicable), and added the copy of 
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prescription form and the confirmation sheet of assigned medication to send (via fax) to 
the clinical trials pharmacy, where the treatment is prepared and dispensed. During the 
treatment, the study nurse of daily hospital is responsible to record the date in the 
patient’s records (usually, included date and time of treatment administration, records of 
vital signs before, during and after the treatment, among others). 
o Documents, CRFs, AEs and SAEs Report: After the visit, I reviewed all source documents 
(signed and dated) and new data generated. I also verified if the information required and 
contemplated in the visit guide, was completed in clinical processes by investigator as well 
as the records about the treatment administration filled by study nurses. 
During my internship, I filled the eCRFs of many studies in which I introduced large amount 
of data. Thus, it was important to have the patient´s records completed with all required 
information because I needed to introduce the same in the eCRFs. When, any information 
was not totally clarified or there was missing data, I took notes in order to be explained or 
added by the investigator. Thus, information should be correctly recorded in all patient´s 
records to become the data entry, a more efficient activity.  
I also had the opportunity to participate in the SAEs reporting. By GCP a SAE must be 
reported in 24 hours after the awareness of PI or sub investigator who fills a SAE from or 
enter the SAE data directly in the patient CRF (27). After the investigator fills the SAE form, I 
sent to the CRA and pharmacovigilance of the study within 24 hours after being detected. 
When I received queries related to the SAE report, I contacted the investigator in order to 
answer to the queries and clarify data. A report of the existing SAEs for a clinical trial is 
gathered, being transformed in Suspected Unexpected Serious Adverse Reactions that 
investigator have to be aware of. 
o Packaging and Sending biological samples: When, per protocol, it was necessary to send 
a biological sample (solid tumours) of a patient to a country, I performed the following 
tasks: 
 Fill the sample request to the service of pathological anatomy; 
 Receive the sample from the service of pathological anatomy; 
 Organise the sample kit and package the sample according to the manual 
instructions; 
 Contact the carrier of the biological sample and register the reference number of 
sample. 
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During my internship, I participated in the packaging and sending of many biological samples 
of solid tumours. The processing, packaging and sending of blood samples were done by the 
study nurse. Additionally, when the tumour block was returned to the UIC, I delivered the 
biological sample to the service of pathologic anatomy with the minimum data required. 
o Other activities performed after the visits: after the patient’s visits, I performed some 
administrative, bureaucratic and data entry activities. Each SC acquires a patient clinical 
trial file, which contains information about exams, requisitions and results of the patient 
included in clinical trial. These files are archived in each SC room according to each 
pathology division. Thus, after the patient clinical visit, I archived the documents in that file 
in order to facilitate the data entry in eCRF. 
According to the Law nº 46/2004, of August 19th (51), a patient that participates in a clinical 
trial has the right to be reimbursed for expenses performed during the participation on the 
same. The UIC has an internal regulation that sustains the way to protect the patient in order 
to be aware of the type of expenses that are paid. Thus, UIC achieves a transparent 
procedure way with the patient payment. For further understanding the procedures occur as 
following: the patient delivers the expenses;  
 I checked these expenses according to the patient clinical visits and dates; 
 I filled a specific expenses form where I reported all expenses and visits; 
 I sent the expenses from to the financial assistant who is responsible for sending the 
information to the sponsor/CRO. 
o Patient’s Discontinuation: a patient may discontinue participation in a study due to the 
following reasons (49): 
 The patient withdrew the consent to participate in the study and intends to abandon 
the same;  
 Unacceptable toxicity resulting from drugs and/or study procedures;  
 Pregnancy; 
 Failure of a procedure and / or the study protocol, which prevents the final analysis of 
the patient; 
 Loss of contact with the patient; 
 Medical decision for safety reasons;  
 Interruption of the trial for safety or lack of efficacy reasons.  
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The last reason is one that most applies to the patient’s discontinuation in oncology 
protocols. During my internship, I discontinued several patients due to the progressive 
disease. This reason is related to the interruption of trial due to the lack of efficacy of 
treatment.  When, any exam or analytical parameter result demonstrate progressive disease, 
the investigator communicated immediately to patient their clinical trial exclusion. 
Subsequently, according to the protocol, I scheduled and prepared the end of trial visit. In 
this visit, the investigator registered the information related to the patient´s discontinuation in 
the clinical process. Through the IWRS/IVRS system, I discontinued the patients. The 
discontinuation confirmation sheet was sent via fax or email, and then, it was archived in the 
patient file. I also introduced the new data into the eCRF. In addition, the patient’s 
discontinuation and related information was communicated to the sponsor/CRO and CRAs. 
3.3.3 Monitoring Visits  
During a monitoring visit the CRA oversees the progress of the clinical trial and ensures that 
it is conducted, recorded and reported according to the GCP and the applicable regulatory 
requirements (27). These visits are performed by qualified CRA’s (properly trained and with 
specific scientific and clinical knowledge) appointed by the sponsor of each study. The 
purposes of monitoring visits are (27):  
 Protection of rights and well-being of human subjects; 
 Guarantee that reported trial data is accurate, complete and verifiable from source 
documents; 
 Clinical trial compliance with protocol/amendments, GCP and regulatory 
requirements.  
 During my internship I had the opportunity to participate in some monitoring visits.  
Firstly, under the supervision of another SC delegated to the study, I scheduled the visit with 
CRA, usually by telephone or e-mail, in order to ensure the availability of SC and also the 
presence of the investigator(s) and other team members. Then, I recorded the date in an 
agenda and few days before the monitoring visit, I prepared and organised all essential 
materials to conduct the visit, for example, the patient files, the clinical processes of patients, 
the ISFs and other study dossiers and the CRF. Usually, CRAs sent by email the specific 
objectives of the visit in order to facilitate the preparation of necessary dossiers and 
documentation. Thus, I reviewed all documents to ensure the quality of the data and solve 
outstanding issues, related with queries, AEs and/or SAEs, missing data and unintelligible 
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data. I also checked and completed the eCRFs. If any data needed were missing in the 
clinical processes and/or patient files, I arranged a meeting with the investigator(s), in order 
to clarify the data (and if necessary, the PI performed an electronic amendment in the clinical 
process of patient). If any doubt or outstanding issue persisted, I appointed to solve with the 
CRA in the visit day. After organising the visit, the operational assistants stored the materials 
into the monitoring room until the day of visit. 
During the visit, CRAs explored all documents and I accompanied their work and assisted 
them with my feedback and comprehension of source documents, clarifying issues and 
solving outstanding issues. When it was possible, all issues were solved in the visit day also 
with the collaboration of the investigator. However, there were other issues unable to solve in 
the day of monitoring visit. Hence, I took notes in order to solve them in the next visit 
scheduled. Few days after the visit, CRA sent a follow-up letter of the monitoring visit, 
including a description of the same and outstanding issues. This follow-up letter was very 
important to remember the outstanding issues and solve the same during the right time.  
o Emergency Code Break: code breaking is defined as the breaking of the identification 
code of the blinded drug (49). I had the opportunity to follow the procedures concerning an 
emergency code breaking. Thus, after knowing the trial results by the sponsor/CRO, it 
was scheduled the patient´s visits. The patients were contacted and in the day of visit, the 
investigator explained the trial results to the patients. Then, according to the information 
provided to the investigator, the patient decided to continue or discontinue the trial. 
3.4 Clinical Trial Closeout Activities 
3.4.1 Closeout Visits  
A closeout visit occurs after the last patient has completed all scheduled visits associated 
with the study. Throughout my internship, I did not participate in the tasks related associated 
to a closeout visit. However, I have some knowledge related to the purpose and preparation 
management of a closeout visit.  
Firstly, to close out a study, the sponsor sent to the research team the end of study 
notification. In this visit, there are no more AEs and/or SAEs and queries clarification forms 
have been resolved, the database is locked and ready for statistical analysis, and the study 
conduct has ended. The whole concept behind a closeout visit is to ensure that everything is 
clarified and archived at the study site file and that the documentation is well organised and 
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will remain intact and be accessible in the future. A closeout visit of a trial can only be 
performed after the CRAs review both investigator/institution and sponsor files and confirmed 
that all required documents are in the adequate files (27). 
3.4.2 Documents Archiving 
 According to the Commission Directive 2005/28/EC of 8 April 2005, the essential documents 
of the clinical trials should be retained for at least five years after its completion. However, 
the documents should be retained for longer periods by an agreement between the sponsor 
and the investigator (55).  The essential documents should be archived to ensure that they 
are available, upon request, to the competent authorities (55). The medical files of subjects 
that participated in the study should be retained according to the national legislation for a 
period of time authorised by the institution (55). In this institution the maximum period of time 
permitted is 15 years (MS p.c.). 
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4. Discussion 
The completion of my internship enabled me to reach a broader vision about the initiation, 
conduction and closeout of clinical trials in the oncology field. The clinical trials coordination 
was the focus of my activities, during which, I experienced difficulties, found challenges, 
developed strategies to combat adversities and, in the end, I acquired on the job experience.  
As presented in the 1.1.2, the UIC was created in 2006 and today has a structured, 
organised and multidisciplinary team, whose members are segmented into well defined 
responsibilities. This fact became my first big challenge because I felt the need to integrate in 
the team and in the work circuit. The progressive knowledge about the structure and UIC 
procedures as well as the roles of UIC team members, specially the roles of a UIC SC’s, 
facilitated my integration and learning process. I consider that this challenge was achieved 
because few months after the beginning of internship, I already felt and performed my 
activities as a team member of UIC. 
According to the clinical R&D course, in European countries, where clinical research already 
reached high levels of maturity, the R&D of new medicines had a direct influence on the 
improvement of health and life quality of populations (4, 21). On the other hand, 
biopharmaceutical R&D also contributed to the wealth creation, through the employability 
and to the improvement of Europe´s trade balance (4, 21). The globalisation and the 
economic  and social development are creating big challenges to the health sector and, more 
specifically, for the pharmaceutical industry (4). During the R&D of new medicines, the 
clinical trials are the major portion of the investment (29). This has been leading the 
pharmaceutical industry to search for places where the clinical trials completion may be more 
efficient (23). The reallocation of clinical trials to the developing countries reflects a loss of 
efficiency and, consequently, lower attractiveness of developed countries for clinical trial 
completion (4, 23). In Portugal, the unfavourable regulatory framework (excessively 
bureaucratic) has been determining this reallocation (4). Thus, the clinical trials are the 
research paradigm of new medicines (4). The clinical research in Portugal has been losing its 
leading position within the overall investment in health (4). I consider this trend 
incomprehensible because my experience enabled me to contact with distinct clinical 
research professionals and understand that Portugal has capable professionals and also a 
good scientific capacity in research and health institutions. I realised that the UIC of IPOP is 
an exception to the negative trend in Portugal, because the number of authorised clinical 
trials and the patient’s recruitment rate has been increasing (4). Once again, my experience 
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enabled to understand and conclude that the key to the success of the UIC of IPOP is  
related to the confidence, motivation, interest and devotion of a multidisciplinary team, 
including the PIs, sub-investigators, manager of GCP and quality, operational manager, SCs 
among others elements and in addition, the continued commitment of IPOP AB. 
 My internship involved generic and specific training components. Therefore, at the beginning 
of my internship, I completed online training courses in ICH/GCP and in Electronic Data 
Capture systems. The first training was essential to conduct all my activities as SC. During 
the Degree and Master´s Course I learned that the understanding and compliance with GCP 
is the key to the success to perform clinical research, assuring that the rights, safety and 
well-being of trial subjects are protected (27). The second training was imperative to perform 
the data entry task and also to introduce large amount of data in the eCRFs of several 
clinical trials protocols. The platform of Electronic Data Capture system may vary according 
to the clinical trial, so I felt the need to perform the online training courses in three different 
platforms (referred 1.2). These online courses introduced me to the specific platform and 
ensure that I was able to perform the data entry task. I also consider that the understanding 
about the characteristics, symbology and management of each platform enabled to improve 
my performance in data entry in eCRF. On the other hand, I also felt the need to deepen my 
understanding about concepts and classification systems found in the oncology clinical trials 
protocols that are daily used by healthcare professionals in medical records and exams of 
clinical trials subjects. I designated them as support tools. My acquaintance with these tools 
enabled me to better understand the contents of medical records and exams, use and apply 
them in an accurate manner (for example, in the tasks performed before, during and after the 
patient clinic visits). 
During my specific training of internship, I had the opportunity to participate in 6 phase II and 
25 phase III clinical trials of different clinics of pathology. I recognise that this opportunity was 
very important because I acquired a greater knowledge and experience in oncology protocols 
of different therapeutic indications (including solid and liquid tumours). The clinical trials 
indicated to test new treatments (or new treatment combinations) for liquid tumours required 
a larger amount of procedures as well as a large complexity of the same. Thus, I consider 
the Onco-Haematology as the clinic of pathology with the more complex clinical trials 
protocols according to my experience as SC. 
 Considering the clinical trials coordination activities - initiation, conduction and closeout – I 
did not provide a similar contribution in the three steps. I participated intensively in the clinical 
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trial conduction activities. My disproportionate contribution to the steps referred above was 
due to the fact that UIC team members have already well defined roles, functions. In 
addition, some tasks (for example the tasks that occur until the clinical trial approval) are 
confined to other UIC professionals (operational manager and manager of GCP and quality). 
Nevertheless, I deepened and consolidated theoretical knowledge in tasks that I did not 
execute because I had an oral session in which it was explained the content and the order in 
which they happen.  
With respect to the clinical trial conduction activities, I accomplished and performed them 
according to distinct oncology protocols for several oncology diseases, including different 
study designs and procedures. I acquired a greater knowledge about cancer disease, 
including diagnostic and assessment methods and therapeutics associated. 
During my internship, I had the opportunity to participate in a clinical trial initiation activity that 
was useful because it enabled to get a deep understanding about the clinical trial procedures 
as well as some particularities related to the study. On the other hand, the background 
acquired during this visit facilitated the work of the SC in supporting the research team 
members.  
The conduction of a clinical trial was very challenging. For each clinical trial, there was a 
research team constituted by professionals with a different way of working and organisation. 
Therefore, I needed to adapt, work together and meet the expectations of different 
professionals, including investigators and CRAs. I realised that each investigator had its own 
way of working and when new situations and doubts appeared they must be solved quickly 
and safely.  Each screening, randomisation or clinical visit were carefully scheduled and 
prepared ensuring that timings and procedures were compliant with protocol. I felt the need 
to establish good communication flows between not only investigators but also study nurses 
(responsible for blood sample collection and treatment administration), assuring the 
acquaintance of them with procedures, its completion and execution according to the 
protocol. The organisation and planning of conduction activities was a good work 
methodology because this enabled to distinguish the tasks according to the priority. Also, the 
data collection and verification (after clinic visits, for example) was useful because all patient 
data must be recorded, since, what is not recorded, does not exist. Then, the organisation of 
source data in respective dossiers ensured to protect and maintain updated data. This task 
was very useful because when I needed to introduce the data into eCRF, I already had the 
necessary clinical patient records archived into the dossiers. Thus, I could follow in detail the 
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clinical condition of patients and, at the same time, the work was prepared to support the 
periodic monitoring visits. This task tested my ability to communicate and opinion share. My 
support in the periodic monitoring visits and the contact with CRAs helped me to overcome 
some fears. The interaction, exchange of experience and training with CRA strengthened the 
work between two different professionals of clinical research. Consequently, the results of 
this cooperation were reflected in an improvement of work efficiency. I acquainted myself 
with CRA functions and roles and understood that a good work preparation to these visits will 
be preponderant to assist the both functions. Thus, my contribution in monitoring visits was 
very important to adjust and improve my performance as SC. 
In order to conclude my challenges and positive marks experienced during my internship, it is 
important to emphasise that the experience as SC enabled me, each day, to face and solve 
new cases and situations. This was very positive for me because I learned to prioritise and 
act when the adversities arise and, consequently, improved my technical and interpersonal 
skills and gained experience as SC trainee. I also felt motivated and enthusiastic to conduct 
the activities as SC trainee during the 8 months of experience. 
On the other hand, I also point some negative aspects that are necessary to improve in the 
future. The first is that, I did not establish a personal contact with the patient other than the 
phone contact. I regard this fact as limiting because the oral communication is a more 
efficient method to know the patient expectations, doubts, fears, as well as family support, 
professional situation and socio-economic conditions. The knowledge of these circumstances 
is essential to protect and safeguard the rights of patient. A referred above, my contribution 
was not in equal terms to the three clinical trial coordination activities. I did not gather know-
how in the initiation and closeout activities and I only have the theoretical knowledge about 
them. The initiation activities are very important to acquaint me about the tasks circuit and 
interactions with regulatory authorities until the clinical trial approval.  During the trainee, I did 
not collaborate in any audit regarded as an opportunity of learning and be aware about what 
the research team should or not do in a clinical trial, quality of team’s work, compliance with 
protocol and legislation and future advice to pursue. An audit is a chance to recognise and 
improve the trial site performance. In addition, during these 8 months, I did not have the 
opportunity to collaborate in observational studies and so to experience, in practice, the 
differences between clinical trials and observational studies. 
In addition to the positive and negative marks presented, I experienced difficulties and 
developed strategies to combat them. My first difficulty was to understand and integrate 
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myself in the UIC multidisciplinary team.  In order to overcome this difficulty, I tried to 
understand and acquaint about the roles and functions of each UIC team member. Then, I 
developed the work according my roles and responsibilities and assisted the clinical research 
team in clinical trial activities. At the end, I communicated sharing my feedback to the UIC 
team members, mainly to the SCs and Operational Manager. Another difficulty was to 
understand the role and the work (activities, tasks and procedures) of a SC in the UIC. This 
topic includes the manner as a SC in UIC schedules, prepares and conducts a patient clinic 
visit; the patient’s circuit in the IPOP, during a clinic visit; the communication´s flow and 
interaction between the different research team members (study nurses and investigators, for 
example). The strategy to combat this problem was to put into practice the SC tasks and 
focus on the tasks that for me were more complex to execute. The tasks more difficult 
included my ability to communicate, namely, the ability to transmit ideas and opinion share 
showing the critical spirit with different healthcare professionals. The third difficulty was 
dealing with unexpected situations, involving patients, failure of electronic systems, changes 
in deadlines, among others. These adversities were faced as a challenge. Thus, I needed to 
understand what to do in order to solve the problem, including:  the perception about what 
UIC team members and other professionals were able to assist me, as well as the 
awareness about how to act depending on each situation. This strategy enabled me to 
develop and practice the ability to problem’s solving and establish the priorities according to 
the situation. 
According to my primary and secondary objectives defined in the section 1.2, I have several 
points to criticize.   
In this way, I gathered personal and professional experience, skills and competences 
including: 
o Experience as  clinical trials SC in oncology protocols; 
o Knowledge about protocols for different oncology therapeutic indications, specially the 
protocols of Digestive clinic of pathology; 
o Working tools and methodologies with the experienced work team members: these tools 
facilitated my integration in the work operations; 
o Cooperation with a multidisciplinary team work me to perform, develop and specialise in 
the oncology clinical studies and prepares me to integrate the labour market; 
o Demonstration the ability to achieve the proposed activities in an effectively and efficiently 
manner, fulfilling the deadlines established; 
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o Ability to time management according to the priorities established; 
o Improvement of the critical thinking analysis; 
o Development of positive interpersonal relationships among team members of UIC, 
healthcare professionals and other professionals included in the study team; 
o Demonstration of the problem-solving ability. I developed the ability to communicate with 
clinical research professionals which facilitated my adaptation to the clinical trials 
coordination activities.  
o Improvement the ability to communicate; 
o Professional and personal growth; 
On the other hand, during my internship, I also would like to develop the following 
competences: 
o Experience in all clinical studies coordination activities, in order to become my experience 
as SC complete;  
o Autonomy to perform the type of activities associated with clinical trials and observational 
studies conduction: I did not have the experience in observational studies conduction, 
however, I would like to acquired experience and know-how in these studies; 
o Knowledge and training in the preparation, conduction and reporting of an audit in the 
context of a clinical study:  this is an activity inherent to the clinical research, which I did 
not have the opportunity to collaborate. However, since the beginning of my internship I 
was trained to conduct all my activities in the terms of an audit; 
In sum, the knowledge gathered during the Degree in Biomedical Sciences and Master’s 
Course in Pharmaceutical Medicine was deepened and applied as well as it was enriching 
and motivating to transpose the theoretical knowledge to the practice of clinical research. I 
recognise that the basis acquired during the Master’s Course were very useful to have a 
better understanding and performance in clinical trial coordination activities. In addition, all 
that I learned during my Degree and Master´s Course became clearer. Thus, in general, I 
consider that, inside of the clinical research area, I achieved this knowledge in the field 
related to the clinical trials. Additionally, I wish that in the future, the key stakeholders will join 
forces to promote and strengthen the clinical research in Portugal, specially, in the oncology 
field. 
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5. Conclusions 
This 8-month internship as SC in the UIC of IPOP provided me skills and expertise essentials 
to the coordination of clinical trials in the oncology field. I recognise that I would never 
acquire these skills and competences, if I had not gone through this experience.  
During my internship, I acquired the theoretical basis about how to initiate, conduct and 
closeout a clinical trial in UIC of IPOP. I participated intensively in clinical trial coordination 
conduction activities of several clinics of pathology including Urology, Gynaecology, 
Digestive, Lung, Soft Tissue and Skin, Head and Neck, Onco-Haematology, Breast and 
Paediatry. On the other hand, the experience in the UIC was even more challenging 
because, at the some point of my internship, I acquired more responsibility and autonomy to 
coordinate the clinical trials of the Digestive pathology. This responsibility was not easy and I 
needed to work a lot and overcome some adversities but today I recognise that this 
challenge became an opportunity. Currently, I coordinate the clinical trials of the Digestive 
clinic of pathology. Thus, at this level, I had the opportunity to gain know-how, experience 
and expertise in oncology clinical studies conduction activities as well as I know and 
understand the procedures associated to the operation of UIC, as a clinical research centre.  
The background acquired during the Degree and the first year of Master´s Course in 
Pharmaceutical Medicine influenced, positively, my performance evolution throughout the 
internship as SC. This background was applied, consolidated and enabled to enrich my 
practice associated to the clinical trials. On the other hand, my experience as SC in the UIC 
enabled to improve my interpersonal skills. I felt that I became in a more proactive and 
assertive member, I improved the ability to communicate, transmit and share ideas, opinions 
and also I developed the critical spirit together with the multidisciplinary research team 
members.  
My internship completion enabled me to feel able to initiate a career as a clinical research 
professional, specially a SC. Under this job, I hope to bridge the gaps of my training. Thus, I 
hope to have the opportunity to collaborate, in a similar way, in all clinical trials coordination 
activities and specialise me as SC. 
Thus, after concluding my training, I feel motivated to develop a career the in the clinical 
research area. In the near future, I hope to have the opportunity to contribute to the 
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observational studies. I also wish that pharmaceutical R&D trends will be reversed, 
promoting and strengthening the clinical research in Portugal namely in the oncology field. 
Due to all the reasons presented and discussed, I classify my experience as challenging, 
interesting, motivating and enriching but not complete. Thus, in the near future, I hope to 
gather more and new experience in clinical research area and grow as professional of clinical 
research. 
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